Wednesday, October 8, 2025

Latest

Curaleaf: The Analyst Take On The European Expansion

On April 7th, Curaleaf Holdings (CSE: CURA) announced that they completed $312 million acquisition of related party European company EMMAC Life Sciences, and subsequently they sold 31.5% of the company off to a single institutional investor for U$130 million. This money will be used to pay the $50 million cash tender while the rest of the cash will be used to fund Curaleaf international’s CAPEX through 2022.

Curaleaf currently has 14 analysts covering the company with a weighted 12-month price target of C$27.86. This is up from the average from last month of C$25.14. Four analysts have strong buy ratings and the other ten analysts have buy ratings. The street high comes from BTIG with a C$34 12-month price target and the lowest is C$24 from Cormark Securities.

Canaccord Genuity’s analyst, Matt Bottomley writes, “we believe the potential long-term optionality afforded by entrance into these geographies could be very attractive relative to its current purchase price, time while representing an international platform for potential M&A as these markets develop.” Bottomley believes that this $80 million will go towards the expansion into UK, Germany, Italy, Spain, and Portugal.

Bottomley makes a note that they believe Curaleafs $1.2 – $1.3 billion revenue and 30% EBITDA margin guided by management does not include 1) any contributions from EMMAC and 2) adult-use sales in New Jersey, which is included in their U$1.36 billion 2021 revenue estimate.

Meanwhile, Haywood’s analyst Neal Gilmer says, “The addition of EMMAC not only provides international exposure but positions the company to be a leader in the global cannabis market,” and adds that the strategic investment by a single investor gives legitimacy to the European market. Gilmer also adds that Curaleaf estimates that in 2020 the European medical cannabis market was $1 billion and is expected to >5x in the next three years.

Haywood gives three upcoming catalysts, which you can see below.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Related News

Curaleaf Sees Numerous Analysts Raise Price Targets Following Third Quarter Results

On Tuesday, Curaleaf Holdings (CSE: CURA) reported their third quarter results. The company reported total...

Saturday, November 21, 2020, 01:27:00 PM

CloudMD Gets Price Target Cut By Canaccord Genuity

On Monday CloudMD Software & Services Inc. (TSXV: DOC) reported its fourth quarter results for...

Wednesday, May 4, 2022, 03:06:00 PM

Canopy Growth: Analysts Raise Price Targets Following Q2 Results

On Monday, Canopy Growth (TSX: WEED) (NYSE: CGC) reported its fiscal second quarter 2021 financial...

Thursday, November 12, 2020, 01:17:00 PM

Facebook: Analysts Expect $3.03 In Q2 Earnings Per Share

Facebook (NASDAQ: FB) will be reporting its second quarter financial results today after the markets...

Wednesday, July 28, 2021, 11:20:00 AM

Curaleaf Acquires Final Portion of Florida Operations For C$31.9 Million

Curaleaf Holdings (CSE: CURA) has finally acquired the final portion of its Florida assets as...

Sunday, August 23, 2020, 01:35:00 PM